Drug Information

Drug General Information
Drug ID
D0H5CE
Former ID
DNC005021
Drug Name
4-Pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527174]
Formula
C17H12N4S
Canonical SMILES
C1=CC=C2C(=C1)C(=CC=N2)C3=C(N=C(S3)N)C4=CN=CC=C4
InChI
1S/C17H12N4S/c18-17-21-15(11-4-3-8-19-10-11)16(22-17)13-7-9-20-14-6-2-1-5-12(13)14/h1-10H,(H2,18,21)
InChIKey
SSOAVUCQSQRZGQ-UHFFFAOYSA-N
PubChem Compound ID
11231979
Target and Pathway
Target(s) TGF-beta receptor type I Target Info Inhibitor [527174]
KEGG Pathway MAPK signaling pathway
Cytokine-cytokine receptor interaction
FoxO signaling pathway
Endocytosis
TGF-beta signaling pathway
Osteoclast differentiation
Hippo signaling pathway
Adherens junction
Chagas disease (American trypanosomiasis)
Hepatitis B
HTLV-I infection
Pathways in cancer
Colorectal cancer
Pancreatic cancer
Chronic myeloid leukemia
PANTHER Pathway TGF-beta signaling pathway
Pathway Interaction Database Glypican 1 network
ALK1 signaling events
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
TGF-beta receptor signaling
Reactome TGF-beta receptor signaling activates SMADs
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
SMAD2/3 Phosphorylation Motif Mutants in Cancer
SMAD2/3 MH2 Domain Mutants in Cancer
TGFBR2 Kinase Domain Mutants in Cancer
TGFBR1 KD Mutants in Cancer
TGFBR1 LBD Mutants in Cancer
WikiPathways TGF Beta Signaling Pathway
p38 MAPK Signaling Pathway
MAPK Signaling Pathway
TGF beta Signaling Pathway
Extracellular vesicle-mediated signaling in recipient cells
Cardiac Hypertrophic Response
Signaling by TGF-beta Receptor Complex
Integrated Pancreatic Cancer Pathway
Integrated Breast Cancer Pathway
References
Ref 527174J Med Chem. 2004 Aug 26;47(18):4494-506.Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
Ref 527174J Med Chem. 2004 Aug 26;47(18):4494-506.Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.